Loading…
BWAY
Brainsway Ltd.
NASDAQ· Healthcare· Medical Devices· CUSIP 10501L106
$14.30-0.69%Price as of Aug 29, 18:32 UTC · updated once a day, after the close
Key metrics
- Market cap
- $574.7M
- P/E
- 62.2x
- Forward P/E
- 29.4x
- P/B
- 7.0x
- Dividend yield
- —
- Payout
- —
- EPS
- $0.23
- ROE
- 12.82%
- Profit margin
- 15.55%
- Revenue growth
- +35.40%
- Beta
- 0.10
- 52-week high
- $17.40
- 52-week low
- $7.14
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▲ +225.4% over 5Y.
today you would have $3,302.73▲ +230.3%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $9.51 | $4.72 | $3.24 | $1.24 | |
| P/E | — | — | 52.4x | — | — |
| P/S | 3.9x | 7.1x | 4.3x | 3.4x | 1.5x |
| P/B | 2.7x | 5.1x | 2.8x | 2.6x | 0.9x |
| EPS | — | $0.09 |
Fair price, seven ways
Seven formulas applied to what the company reported. None of them predicts a price — each answers what the stock would be worth if its assumption held. The assumption is printed next to every number, because it is the assumption that produces the result.
Earnings
$3.25
Square root of 22.5 × earnings × book value — the two ceilings Graham proposed. Blind to intangibles, so it undervalues software and brands.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
$5.16
Median P/E of 22.4 among peers in the sector.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Cash flow
$8.37
Cash flow growing 5.0% a year for 10 years, discounted at 10%, then 2.5% forever.
Operating
$5.45
Sector median of 13.3x operating profit, less net debt. Sees the business before its financing, so debt does not distort the comparison. Banks have no EBITDA — interest is their revenue, not a cost.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ALLOAllogene Therapeutics, Inc. | $1.67 | — | 1.3x | — | -42.39% | $576.97M |
| BLSMBlossomHill Therapeutics, Inc. | $19.56 | — | — | — | — | $568.83M |
| DCTHDelcath Systems Inc | $16.34 | 1634.0x | 4.7x | — | 0.47% | $566.98M |
| MPLTMapLight Therapeutics, Inc. | $12.60 |
About the company
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
- 129
- Jerusalem, Israel
Company description provided by Yahoo Finance.